COVID-19 (Coronavirus)

Prospective, Multicenter Registry for Short Bowel Syndrome

Condition: Short bowel syndrome

Eligibility

Key Inclusion Criteria:

  • Diagnosis of SBS
  • Patients who have never received teduglutide treatment must be on parenteral nutrition/IV support for at least 6 months
     

Key Exclusion Criteria:

  • Currently participating in a blinded clinical trial or their extension studies
  • Patients who have never been on parenteral nutrition/IV support

Study Name

A Prospective, Multicenter Registry for Patients With Short Bowel Syndrome (IRB no. 51530)

Summary

The purpose of this registry study is to evaluate safety and clinical outcomes in patients with short bowel syndrome (SBS). The study aims to determine whether patients who take teduglutide (a medication for short bowel syndrome) are at a higher risk of developing colon cancer than those who do not take teduglutide.

Researchers will collect data regarding the clinical course and outcomes of SBS in participants who are or are not treated with teduglutide in a routine clinical setting. Information about side effects that potentially could have occurred due to teduglutide will also be collected. Participants will continue to have the medical care they would normally have and will not undergo any additional medical treatments, procedures, or tests as a result of participating in this registry.

Principal Investigator
Contact